Linked Life Data

12901342

Source:http://linkedlifedata.com/resource/pubmed/id/12901342

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-8-6
pubmed:abstractText
Myelodysplastic syndromes are clonal stem cell disorders, and allogeneic hemopoietic cell transplantation (HCT) is the only therapy with curative potential. Among patients with less-advanced myelodysplastic syndromes, 3-year survivals of 65% to 75% are achievable with human leukocyte antigen (HLA)-identical related and HLA-matched unrelated donors. The probability of relapse is less than 5%. Among patients with advanced disease (> or = 5% marrow blasts), 35% to 45% and 25% to 30%, respectively, are surviving in remission after transplantation from related or unrelated donors. The incidence of post-transplant relapse is 10% to 35%. Criteria of the International Prognostic Scoring System, originally developed for nontransplanted patients, also predict relapse and survival after HCT. Refined conditioning regimens have permitted successful HCT even in patients in their seventh decade of life. Results with a regimen using a combination of busulfan (targeted to predetermined plasma levels) and cyclophosphamide are particularly encouraging. Improved survival with transplants from unrelated volunteer donors reflects selection of donors on the basis of high-resolution (allele-level) HLA typing. Nevertheless, transplant-related morbidity and mortality, including graft-versus-host disease, remain challenges that need to be addressed with innovative approaches. Some patients who achieve a chemotherapy-induced complete remission may also benefit from autologous HCT.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1540-3408
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
209-16
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Hemopoietic cell transplantation for myelodysplastic syndromes.
pubmed:affiliation
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, PO Box 19024, Seattle, WA 98109, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review, Research Support, Non-U.S. Gov't